{"title":"Cutaneous Larva Migrans.","authors":"A. Leung, B. Barankin, K. Hon","doi":"10.2174/1872213X11666170110162344","DOIUrl":null,"url":null,"abstract":"BACKGROUND\nCutaneous larva migrans is one of the most common skin diseases reported in travelers returning from tropical regions. Western physicians, however, are often not familiar of this condition.\n\n\nOBJECTIVE\nTo review in depth the epidemiology, pathophysiology, clinical manifestations, complications, and treatment of cutaneous larva migrans.\n\n\nMETHODS\nA PubMed search was completed in Clinical Queries using the key term \"cutaneous larva migrans\". The search included meta-analyses, randomized controlled trials, clinical trials, and reviews. Patents were searched using the key term \"cutaneous larva migrans\" from www.google.com/patents, www.uspto.gov, and www.freepatentsonline.com.\n\n\nRESULTS\nCutaneous larva migrans is a zoonotic infestation caused by penetration and migration in the epidermis of filariform larva of different kinds of animal hookworms through contact with feces of infected animals. Cutaneous larva migrans is endemic in tropical and subtropical regions. Clinically, cutaneous larva migrans is characterized by an intensely pruritic erythematous migrating tortuous or serpiginous, slightly raised track. The diagnosis is mainly clinical, based on the history of travel to an endemic area and exposure to contaminated soil/sand and the characteristic serpiginous track. Treatment options as well as recent patents related to the management of cutaneous larva migrans are also discussed. Compared with oral antihelminthics, topical treatment over the affected area is less effective. Oral ivermectin is the treatment of choice.\n\n\nCONCLUSION\nThe pruritic serpiginous track is pathognomonic. Oral ivermectin is the treatment of choice.","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":"11 1 1","pages":"2-11"},"PeriodicalIF":4.2000,"publicationDate":"2017-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent patents on inflammation & allergy drug discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1872213X11666170110162344","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 7
Abstract
BACKGROUND
Cutaneous larva migrans is one of the most common skin diseases reported in travelers returning from tropical regions. Western physicians, however, are often not familiar of this condition.
OBJECTIVE
To review in depth the epidemiology, pathophysiology, clinical manifestations, complications, and treatment of cutaneous larva migrans.
METHODS
A PubMed search was completed in Clinical Queries using the key term "cutaneous larva migrans". The search included meta-analyses, randomized controlled trials, clinical trials, and reviews. Patents were searched using the key term "cutaneous larva migrans" from www.google.com/patents, www.uspto.gov, and www.freepatentsonline.com.
RESULTS
Cutaneous larva migrans is a zoonotic infestation caused by penetration and migration in the epidermis of filariform larva of different kinds of animal hookworms through contact with feces of infected animals. Cutaneous larva migrans is endemic in tropical and subtropical regions. Clinically, cutaneous larva migrans is characterized by an intensely pruritic erythematous migrating tortuous or serpiginous, slightly raised track. The diagnosis is mainly clinical, based on the history of travel to an endemic area and exposure to contaminated soil/sand and the characteristic serpiginous track. Treatment options as well as recent patents related to the management of cutaneous larva migrans are also discussed. Compared with oral antihelminthics, topical treatment over the affected area is less effective. Oral ivermectin is the treatment of choice.
CONCLUSION
The pruritic serpiginous track is pathognomonic. Oral ivermectin is the treatment of choice.
期刊介绍:
Recent Patents on Inflammation & Allergy Drug Discovery publishes review articles by experts on recent patents in the field of inflammation and allergy drug discovery e.g. on novel bioactive compounds, analogs and targets. A selection of important and recent patents in the field is also included in the journal. The journal is essential reading for all researchers involved in inflammation and allergy drug design and discovery.